advers
event
follow
immun
aefi
advers
event
special
interest
aesi
treescan
b
r
c
live
viral
vector
express
heterolog
antigen
target
pathogen
investig
develop
novel
vaccin
seriou
infecti
agent
like
hiv
ebola
live
recombin
vector
vaccin
may
replicationcompet
key
challeng
defin
length
time
monitor
potenti
advers
event
follow
immun
aefi
clinic
trial
epidemiolog
studi
time
period
must
chosen
care
base
consider
preclin
clinic
trial
data
biolog
plausibl
practic
feasibl
avail
option
includ
adapt
current
relev
regulatori
guidelin
conven
panel
expert
review
evid
systemat
literatur
search
narrow
list
like
potenti
known
aefi
establish
optim
risk
window
conduct
near
realtim
prospect
monitor
unknown
cluster
aefi
valid
larg
link
vaccin
safeti
databas
use
rapid
cycl
analysi
prespecifi
advers
event
special
interest
aesi
treescan
identifi
previous
unsuspect
outcom
risk
window
establish
option
could
use
along
establish
registri
clinic
valid
prespecifi
aesi
includ
casecontrol
studi
depend
infrastructur
human
resourc
databas
avail
differ
countri
appropri
option
combin
option
determin
regulatori
agenc
investig
viral
vector
vaccin
safeti
surveil
durat
advers
event
follow
immun
aefi
advers
event
special
interest
aesi
treescan
b
r
c
live
viral
vector
express
heterolog
antigen
target
pathogen
investig
develop
novel
vaccin
seriou
infecti
agent
like
hiv
ebola
live
recombin
vector
vaccin
may
replicationcompet
key
challeng
defin
length
time
monitor
potenti
advers
event
follow
immun
aefi
clinic
trial
epidemiolog
studi
time
period
must
chosen
care
base
consider
preclin
clinic
trial
data
biolog
plausibl
practic
feasibl
avail
option
includ
adapt
current
relev
regulatori
guidelin
conven
panel
expert
review
evid
systemat
literatur
search
narrow
list
like
potenti
known
aefi
establish
optim
risk
window
conduct
near
realtim
prospect
monitor
unknown
cluster
aefi
valid
larg
link
vaccin
safeti
databas
use
rapid
cycl
analysi
prespecifi
advers
event
special
interest
aesi
treescan
identifi
previous
unsuspect
outcom
risk
window
establish
option
could
use
along
establish
registri
clinic
valid
prespecifi
aesi
includ
casecontrol
studi
depend
infrastructur
human
resourc
databas
avail
differ
countri
appropri
option
combin
option
determin
regulatori
agenc
investig
immun
vaccineprevent
diseas
vpd
highli
costeffect
public
health
intervent
tradit
method
vaccin
develop
sever
major
human
pathogen
may
less
optim
new
biotechnolog
approach
explor
includ
develop
recombin
viral
vector
vaccin
use
attenu
viru
carri
introduc
viral
dna
antigenpres
cell
induc
humor
cellmedi
immun
respons
vector
refer
viru
use
carrier
live
viral
vector
express
heterolog
antigen
target
pathogen
vivo
investig
develop
vaccin
human
immunodefici
viru
type
plasmodium
falciparum
influenza
sever
acut
respiratori
syndrom
coronaviru
sarscov
ebola
viru
hepat
c
viru
respiratori
syncyti
viru
mycobacterium
tuberculosi
middl
east
respiratori
syndrom
mer
lassa
fever
nipah
chikungunya
zika
virus
etc
see
tabl
live
recombin
viral
vector
vaccin
includ
replicationdefect
replicationcompet
virus
possibl
associ
two
differ
heterolog
vector
primeboost
regimen
replicationdefect
vector
may
natur
hostrestrict
avipox
vector
may
attenu
either
serial
passag
eg
yellow
fever
viru
less
virul
decreas
replic
compet
human
eg
modifi
vaccinia
ankara
genet
engin
limit
replic
less
singl
cycl
abort
replic
eg
case
adenoviru
vector
heterolog
antigen
gene
may
viral
bacteri
parasit
oncolog
gene
therapybas
heterolog
gene
may
compris
sequenc
code
portion
antigen
entir
antigen
one
antigen
heterolog
antigen
gene
one
infecti
agent
case
protect
wildtyp
viru
vector
deriv
may
also
sought
immun
respons
induc
live
recombin
vectoredvaccin
depend
extent
durat
replic
vector
immunogen
express
heterolog
antigen
antigen
vector
virul
live
recombin
viral
vaccin
predict
viral
vector
even
vector
alreadi
attenu
human
emphas
need
extens
safeti
studi
clinic
develop
public
health
use
even
critic
vector
nonhuman
viru
origin
util
inform
pathogen
wildtyp
viru
human
may
limit
absent
potenti
revers
virul
recombin
reassort
circul
wildtyp
virus
also
must
consid
viral
vector
may
demonstr
ident
safeti
profil
express
differ
foreign
antigen
see
tabl
note
earlier
list
recombin
viral
vector
preclin
clinic
develop
expand
thousand
subject
enrol
clinic
develop
control
variou
infecti
diseas
recombin
adenoviru
poxvirus
advanc
platform
given
larg
number
candid
vaccin
clinic
studi
world
health
organ
us
food
drug
administr
fda
european
medicin
agenc
ema
provid
variou
guidanc
document
identifi
appropri
regulatori
pathway
develop
gap
critic
data
set
support
advanc
viral
vectorbas
vaccin
licensur
brighton
collabor
form
viral
vector
vaccin
safeti
work
group
octob
help
standard
collect
analysi
dissemin
safeti
data
regard
tabl
viral
vector
vaccin
candid
differ
stage
develop
use
human
ing
viral
vector
vaccin
preand
postlicensur
set
hope
improv
abil
anticip
safeti
issu
meaning
assess
interpret
safeti
data
clinic
trial
new
viral
vectoredvaccin
enhanc
safeti
knowledg
well
public
confid
vaccin
uptak
licens
one
way
enhanc
understand
vectoredvaccin
safeti
improv
surveil
advers
event
follow
immun
aefi
vaccin
associ
advers
event
vaer
sponsor
cdc
fda
use
sinc
see
robust
vaccin
safeti
monitor
mani
advantag
includ
discoveri
potenti
novel
unanticip
advers
event
associ
vector
vaccin
develop
use
safer
vaccin
minim
risk
advers
event
ae
vaccin
provid
specif
recommend
includ
contraind
precaut
use
live
recombin
vectoredvaccin
may
integr
one
key
challeng
defin
length
time
monitor
potenti
relat
aefi
receipt
viral
vectoredvaccin
time
period
must
chosen
care
base
consider
clinic
trial
data
biolog
plausibl
followup
time
must
long
enough
includ
plausibl
period
increas
risk
also
call
risk
window
risk
interv
b
comparison
control
nonrisk
time
period
studi
design
period
occur
post
vs
pre
risk
window
studi
vaccineassoci
guillain
syndrom
gb
risk
interv
includ
day
vaccin
vaccineassoci
gb
consid
biolog
plausibl
control
interv
day
vaccin
number
event
type
tabul
week
number
ae
postvaccin
window
compar
number
prevaccin
window
caseonli
selfcontrol
method
also
refer
selfcontrol
case
seri
scc
commonli
use
influenza
vaccin
safeti
studi
elimin
betweenperson
bias
scc
prefer
studi
design
avoid
healthi
vaccine
effect
hve
commonli
associ
prerisk
control
window
hve
refer
fact
individu
ill
recent
hospit
otherwis
unwel
vaccin
may
defer
health
care
provid
patient
primari
caregiv
health
individu
improv
consider
especi
true
vaccin
earli
infanc
therefor
vaccin
individu
like
healthi
state
immedi
vaccin
consequ
hve
reduc
ae
rate
immedi
preand
postvaccin
period
reduc
power
detect
ae
select
surveil
durat
short
long
could
caus
true
increas
risk
miss
obscur
random
nois
ideal
durat
base
statist
power
consider
eg
continu
power
achiev
detect
minimum
absolut
excess
risk
import
public
health
continu
import
risk
rule
due
differ
background
rate
specif
aesi
length
plan
surveil
may
differ
outcom
vaccin
studi
aesi
may
take
time
manifest
detect
eg
vsv
ebola
vaccin
found
synovi
fluid
caus
arthriti
long
durat
monitor
often
challeng
lowand
middleincom
countri
lmic
limit
health
infrastructur
countri
evolv
aefi
monitor
system
multipl
prioriti
even
countri
excel
infrastructur
challeng
new
diseas
new
vaccin
avail
option
defin
optim
length
followup
use
clinic
trial
epidemiolog
studi
new
pharmaceut
product
includ
viral
vectoredvaccin
candid
mention
adapt
current
relev
exist
guidelin
risk
interv
work
group
clinic
immun
safeti
assess
network
cisa
form
septemb
due
critic
role
correct
specif
risk
control
interv
aefi
play
observ
studi
vaccin
safeti
rel
pauciti
work
done
formal
assess
determin
biolog
plausibl
evidencebas
risk
interv
group
use
febril
seizur
acut
dissemin
encephalomyel
model
provid
indepth
review
methodolog
issu
relat
select
risk
control
interv
consider
futur
studi
immun
safeti
knowledg
risk
profil
rel
time
sinc
immun
mani
aefi
often
incomplet
choos
one
eg
short
long
biolog
plausibl
risk
interv
evalu
activ
surveil
studi
may
appropri
fda
guidanc
gene
therapi
clinic
trial
observ
subject
delay
advers
event
current
explicitli
state
appli
vaccin
use
prevent
infecti
diseas
even
use
product
analog
use
gene
therapi
nevertheless
guidanc
may
provid
start
upper
bound
plausibl
risk
interv
may
adjust
downward
shorter
interv
appropri
scientif
rational
exampl
guidanc
recommend
minimum
followup
possibl
shorter
risk
period
tabl
safeti
issu
consider
candid
viral
vector
vaccin
characterist
pathogenesi
known
advers
event
wildtyp
viru
viral
vector
incorpor
foreign
antigen
final
recombin
viral
vector
vaccin
data
complet
viral
vector
vaccin
safeti
work
group
templat
help
determin
potenti
gener
replicationcompet
viru
replicationdefect
viral
vector
measur
immun
respons
antigen
present
replicationcompet
virus
absent
replicationdefect
virus
might
help
identifi
situat
potenti
revers
viral
vector
virul
might
also
occur
manufactur
batch
vaccin
vaccin
recipi
potenti
recombin
reassort
infecti
agent
might
coincident
occur
vaccine
around
time
dose
incid
viremia
assess
extent
durat
vaccin
shed
potenti
transmiss
live
vector
vaccin
contact
potenti
vaccin
trigger
autoimmun
diseas
potenti
integr
gene
deriv
vector
host
genom
consider
specif
advers
event
might
reflect
distribut
vector
specif
bodi
site
potenti
certain
advers
reaction
occur
subset
eg
particular
genet
predisposit
potenti
increas
suscept
infect
agent
protect
sought
due
high
level
immun
vector
viru
potenti
nucleotid
mutat
result
chang
immunogen
affect
vaccin
effect
potenti
viral
vector
induc
toler
evidenc
poor
vaccin
efficaci
clinic
trial
epidemiolog
studi
support
evid
avail
eg
durat
vivo
vector
persist
transgen
express
feasibl
etc
fda
guidanc
consider
design
earlyphas
clinic
trial
cellular
gene
therapi
cgt
product
state
year
followup
appropri
subject
earlyphas
trial
one
sourc
relev
guidanc
suit
resourcelimit
set
come
matern
immun
trial
minimum
recommend
followup
period
women
month
postdeliveri
follow
earli
termin
pregnanc
minimum
recommend
followup
period
infant
year
age
guidanc
also
allow
shorter
longer
followup
period
adequ
scientif
justif
appropri
durat
followup
depend
result
preclin
studi
experi
relat
product
knowledg
diseas
process
biolog
characterist
vaccin
vaccinetarget
diseas
aesi
includ
outcom
identifi
previou
trial
characterist
vaccin
recipi
eg
nutrit
state
underli
diseas
immunecompromis
condit
associ
comorbid
condit
intent
assess
earli
childhood
develop
case
vaccin
pregnant
women
lateonset
outcom
part
risk
manag
plan
may
requir
followup
period
year
guidelin
acknowledg
signific
logist
challeng
extend
followup
period
especi
resourcelimit
set
gener
longterm
monitor
focus
subject
surviv
seriou
advers
event
aesi
could
includ
hematolog
immunolog
neurolog
oncolog
aesi
purpos
telephon
call
subject
rather
clinic
visit
may
suffici
obtain
necessari
followup
inform
addit
complet
longterm
monitor
usual
necessari
prior
initi
subsequ
trial
submit
market
applic
nevertheless
longterm
monitor
lmic
util
modern
data
collect
methodolog
recipi
track
detect
aefi
need
new
viral
vector
vaccin
first
introduc
lmic
countri
otherwis
new
vaccin
largescal
use
may
delay
data
gather
countriesset
appropri
infrastructur
conven
panel
expert
review
evid
systemat
literatur
search
narrow
list
like
known
aefi
establish
optim
risk
window
delphi
techniqu
well
suit
consensusbuild
may
consid
panel
util
seri
questionnair
deliv
use
multipl
iter
collect
data
panel
select
subject
provid
anonym
respond
control
feedback
process
suitabl
varieti
statist
analysi
techniqu
interpret
data
subject
select
time
frame
conduct
complet
studi
possibl
low
respons
rate
unintent
guid
feedback
respond
group
area
consid
design
implement
delphi
studi
new
viral
vectoredvaccin
candid
would
involv
conven
panel
expert
appropri
understand
biolog
mechan
action
new
viral
vectoredvaccin
aesi
may
plausibl
caus
like
onset
time
frame
occurr
expert
panel
recent
conven
instrument
develop
vaccin
safeti
datalink
vsd
white
paper
priorit
studi
safeti
routin
childhood
immun
schedul
specif
aesi
like
risk
interv
prespecifi
hypothesi
exist
pharmacovigil
pharmacoepidemiolog
infrastructur
design
preand
postmarket
marshal
detect
need
valid
safeti
signal
expertbas
approach
wide
use
histor
list
previous
unsuspect
ae
pharmaceut
product
wide
use
long
unlik
efficaci
effect
vaccin
safeti
measur
directli
human
clinic
trial
typic
conduct
use
healthi
nonpregn
volunt
safeti
assess
focus
common
shortterm
prespecifi
local
system
ae
eg
pain
inject
site
fever
rare
seriou
advers
event
associ
vaccin
drug
often
nearli
imposs
detect
account
select
enrol
limit
followup
subject
prelicensur
studi
detect
requir
conduct
postmarket
monitor
also
call
pharmacovigil
introduct
gener
popul
fda
also
requir
divers
popul
studi
incid
aefi
might
vari
differ
popul
safeti
product
infer
rel
absenc
aesi
popul
expos
new
pharmaceut
product
interest
suffici
larg
divers
monitor
adequ
absolut
safeti
understand
desir
goal
difficult
assess
let
alon
guarante
especi
earli
lifecycl
new
product
realtim
prospect
monitor
unknown
cluster
aefi
set
valid
larg
link
vaccin
safeti
databas
tradit
passiv
surveil
also
call
spontan
report
system
serv
rel
afford
first
line
sourc
signal
previous
unknown
aefi
practic
conduct
manual
individu
case
review
usual
augment
implement
computer
data
mine
algorithm
entir
meddra
code
advers
event
databas
detect
pattern
disproportion
report
advers
event
us
fda
ema
mandatori
requir
passiv
report
aefi
vaccin
advers
event
report
system
vaer
eudravigil
system
respect
world
health
organ
help
mani
lmic
improv
capac
monitor
aefi
effort
could
help
upgrad
capac
monitor
aefi
longer
follow
period
includ
code
aefi
icd
intern
classif
diseas
meddra
medic
dictionari
regulatori
activ
etc
beyond
short
followup
period
current
use
help
overcom
mani
methodolog
limit
passiv
surveil
aefi
eg
underreport
bias
report
lack
control
group
sever
highincom
countri
develop
activ
surveil
system
aefi
analys
associ
vaccin
one
prespecifi
advers
health
outcom
exampl
cdc
creat
vaccin
safeti
datalink
vsd
project
collabor
sever
manag
care
organ
vsd
use
distribut
data
model
deidentifi
intern
classif
diseas
icd
code
data
download
individu
electron
health
record
track
use
health
servic
member
particip
site
includ
inform
vaccin
eg
vaccin
type
date
vaccin
vaccin
given
day
specif
medic
ill
diagnos
doctor
offic
urgent
care
visit
emerg
depart
visit
hospit
stay
aefi
need
code
accur
abl
found
databas
us
fda
overse
complementari
activ
safeti
surveil
system
vaccin
call
postlicensur
rapid
immun
safeti
monitor
prism
program
consist
mostli
insur
claim
program
attempt
move
healthcar
record
bring
new
challeng
tradit
vsd
prism
system
conduct
rigor
vaccin
safeti
studi
eg
compar
rate
aefi
within
risk
interv
rate
control
interv
test
hypothes
question
concern
rais
medic
literatur
report
vaer
vsd
studi
usual
take
sever
year
incept
complet
howev
vsd
prism
studi
populationbas
rigor
conduct
gener
address
identif
previous
unsuspect
possibl
advers
reaction
rapid
cycl
analysi
rca
method
vsd
creat
allow
time
eg
weekli
analysi
prespecifi
aesi
prespecifi
risk
interv
public
inform
quickli
possibl
risk
newli
licens
vaccin
new
immun
schedul
rca
use
dynam
data
file
aggreg
data
sequenti
analysi
method
new
signal
detect
method
support
continu
timeperiod
analysi
data
collect
adjust
multipl
statist
test
prism
develop
rca
capabl
also
reliabl
registri
countri
like
denmark
sweden
studi
excitingli
prospect
scan
unknown
cluster
new
aesi
clinic
trial
particip
licens
vaccin
routin
use
gener
popul
becom
realiti
era
larg
data
dream
develop
method
allow
ongo
scan
administr
health
record
pharmaceut
product
exposur
medic
outcom
new
safeti
signal
especi
previous
specifi
given
larg
number
statist
test
done
adjust
multipl
test
need
minim
number
fals
posit
signal
would
otherwis
wast
valuabl
time
resourc
need
assess
true
signal
hope
come
closer
fruition
develop
describ
rca
prespecifi
aesi
treescan
http
wwwtreescan
org
previous
unspecifi
outcom
treescan
novel
scan
statist
method
surveil
conduct
minimum
prior
assumpt
group
vaccin
increas
risk
adjust
multipl
test
inher
mani
potenti
combin
treescan
free
data
mine
softwar
implement
treebas
scan
statist
data
mine
method
simultan
look
excess
risk
larg
number
individu
cell
databas
well
group
close
relat
cell
adjust
multipl
test
inher
larg
number
overlap
group
evalu
develop
diseas
surveil
pharmacovigil
use
simultan
evalu
thousand
potenti
advers
event
group
advers
event
determin
one
occur
higher
probabl
among
peopl
expos
particular
vaccin
particular
diseas
outcom
eg
kidney
failur
use
simultan
evalu
occur
increas
risk
among
peopl
expos
hundr
pharmaceut
drug
vaccin
group
relat
drug
vaccin
http
wwwtreescanorg
treescan
method
allow
wide
rang
unsuspect
potenti
advers
reaction
simultan
evalu
otherwis
unknown
advers
reaction
may
found
main
disadvantag
possibl
adjust
possibl
confound
inde
conclus
causal
base
treescan
analys
alon
effect
treescan
method
serv
tool
identifi
ae
may
merit
care
pharmacoepidemiolog
investig
treescan
begin
use
wide
time
need
assess
effect
eg
aesi
insidi
onset
tradit
challeng
studi
tradit
largelink
databas
use
method
requir
prior
definit
risk
interv
use
treescan
also
like
limit
set
highqual
administr
health
includ
immun
record
initi
lmic
requir
may
like
met
urban
center
indepth
network
site
riskinterv
establish
one
abovement
method
use
follow
option
cancer
field
specif
cancer
diseas
registri
effect
research
tool
casecontrol
studi
particularli
suitabl
studi
rel
rare
diseas
long
induct
period
cancer
possibl
aesi
sinc
case
casecontrol
definit
subject
alreadi
develop
condit
interest
need
wait
time
elaps
similar
approach
taken
safeti
monitor
viral
vector
vaccin
candid
establish
registri
case
identifi
clinic
valid
prespecifi
aesi
match
control
found
hospit
neighborhood
compar
vaccin
exposur
histori
studi
multin
similar
protocol
given
rariti
aesi
like
feasibl
postmarket
surveil
substanti
vaccin
use
occur
set
highqual
administr
health
record
unlik
realiti
near
futur
may
one
possibl
altern
live
viral
vector
express
heterolog
antigen
target
pathogen
vivo
investig
develop
vaccin
numer
infecti
diseas
make
use
varieti
viral
vector
live
viral
vector
vaccin
may
base
replicationdefect
well
replicationcompet
virus
live
recombin
vector
vaccin
may
replic
one
key
challeng
defin
length
time
monitor
aefi
administr
vector
vaccin
clinic
trial
epidemiolog
studi
time
period
must
chosen
care
base
consider
clinic
trial
data
biolog
plausibl
long
durat
monitor
often
challeng
countri
poor
health
infrastructur
countri
evolv
aefi
monitor
system
multipl
prioriti
even
countri
excel
infrastructur
challeng
new
diseas
new
vaccin
avail
option
defin
length
followup
use
studi
new
viral
vector
vaccin
candid
includ
adapt
current
relev
regulatori
guidelin
conven
panel
expert
review
evid
systemat
literatur
search
narrow
list
like
known
aefi
optim
biolog
plausibl
risk
window
conduct
nearrealtim
prospect
monitor
unknown
cluster
aefi
valid
larg
link
vaccin
safeti
databas
eg
vaccin
safeti
datalink
vsd
prism
etc
includ
rapid
cycl
analysi
rca
prespecifi
aesi
treescan
previous
unsuspect
outcom
risk
interv
establish
one
abovement
method
use
along
establish
registri
case
identifi
clinic
valid
prespecifi
aesi
includ
casecontrol
studi
avail
infrastructur
human
financi
resourc
code
databas
countri
regulatori
guidelin
determin
one
combin
method
would
practic
feasibl
option
might
broadli
applic
durat
surveil
new
pharmaceut
product
risk
interv
select
clinic
trial
epidemiolog
studi
may
appropri
length
rule
associ
individu
case
sinc
knowledg
pathophysiolog
mani
aefi
incomplet
longer
risk
interv
may
requir
evalu
aefi
individu
rare
individu
may
genet
immun
defect
result
increas
suscept
vaccin
virus
mortal
rate
vaccin
recipi
defect
may
high
howev
rariti
like
discov
postmarket
analys
find
opinion
conclus
assert
contain
consensu
document
individu
member
work
group
necessarili
repres
offici
posit
particip
organ
eg
govern
univers
corpor
constru
repres
agenc
determin
polici
